Luteal phase sertraline treatment for premenstrual dysphoric disorder - Results of a double-blind, placebo-controlled, crossover study

Objective: To test the efficacy of late-luteal phase dosing of sertraline h ydrochloride in women with moderate-to-severe premenstrual dysphoric disord er. This highly prevalent disorder often causes significant psychosocial im pairment. Design Double-blind, crossover trial of each 2-menstrual cycle of baseline, sertraline treatment, and placebo. Randomization to sertraline treatment v s placebo occurred after a 2-cycle, drug-free period. Setting: A large outpatient multispecialty clinic in central Texas. Patients: Fifty-seven women aged 19 to 49 years with a Diagnostic and Stati stical Manual of Mental Disorders, Fourth Edition, diagnosis of premenstrua l dysphoric disorder. Interventions: Late-luteal phase treatment with sertraline hydrochloride in daily doses of 50 mg (cycle 1) followed by 100 mg (cycle 2) vs placebo. Main Outcome Measures: The 22-item calendar of premenstrual experiences was completed daily and constituted the primary outcome measure, consisting of a total score and behavioral and physical factor scores. Results: A repeated-measures analysis of variance for crossover designs fou nd a significant beneficial effect from sertraline treatment in improving t he calendar of premenstrual experiences total (P<.01), behavioral factor (P <.01), and physical factor (P<.04) scores. Most women improved when taking sertraline, 50 mg, although a dose increase to 100 mg yielded further impro vement in approximately 25% of women. Use of sertraline was extremely well tolerated; the only adverse event reported by 10% or more of women was inso mnia in 8 (14%) of them. Conclusions: Luteal phase treatment with sertraline was a safe and effectiv e treatment for moderate-to-severe premenstrual dysphoric disorder. Further controlled studies are needed to confirm the results of this preliminary s tudy.